MARKET

VNDA

VNDA

Vanda Pharma
NASDAQ
6.15
-0.02
-0.32%
Pre Market: 6.16 +0.01 +0.16% 08:00 07/26 EDT
OPEN
6.05
PREV CLOSE
6.17
HIGH
6.33
LOW
6.01
VOLUME
1
TURNOVER
0
52 WEEK HIGH
6.75
52 WEEK LOW
3.295
MARKET CAP
357.92M
P/E (TTM)
-72.6950
1D
5D
1M
3M
1Y
5Y
1D
Vanda Pharmaceuticals Inc <VNDA.OQ> expected to post a loss of 14 cents a share - Earnings Preview
Vanda Pharmaceuticals Inc expected to post a loss of 14 cents a share. The company is expected to report a 13.7% increase in quarterly revenue to $52.383 million. The average analyst estimate for the company is for a 14 cents per share loss.
Reuters · 3d ago
Weekly Report: what happened at VNDA last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at VNDA last week (0708-0712)?
Weekly Report · 07/15 10:19
Vanda Pharmaceuticals Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 07/11 11:37
Vanda Pharmaceuticals Price Target Announced at $11.00/Share by Cantor Fitzgerald
Dow Jones · 07/11 11:37
Cantor Fitzgerald Initiates Coverage On Vanda Pharma with Overweight Rating, Announces Price Target of $11
Benzinga · 07/11 11:27
Weekly Report: what happened at VNDA last week (0701-0705)?
Weekly Report · 07/08 10:20
*Vanda Will Request Relief From Court That Includes Order Requiring Defendants to Discontinue Marketing Generic Versions of HETLIOZ >VNDA
Dow Jones · 07/01 12:09
More
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Webull offers Vanda Pharmaceuticals Inc. stock information, including NASDAQ: VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.